Analysing the influence of dapagliflozin on urinary tract infection vulnerability and kidney injury in mice infected with uropathogenic Escherichia coli
- 30 September 2024
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (1) , 40-53
Abstract
Aim: Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors have revolutionized clinical medicine, but their association with urinary tract infection (UTI) risk remains debated. This study investigates the influence of dapagliflozin on UTI outcomes, focusing on kidney injury. Materials and Methods: Female non‐diabetic C57BL/6J and C3H/HeOuJ mice, along with diabetic db / db mice, were orally administered dapagliflozin (1 mg/kg or 10 mg/kg) for 7 days before transurethral uropathogenic Escherichia coli (UPEC) infection. Mice were killed either 24 h after UTI or after six additional days of dapagliflozin treatment. UPEC titers were enumerated, and kidney histopathology, injury, fibrosis and function were assessed. Results: Vehicle‐ and dapagliflozin‐treated C57BL/6J mice exhibited similar urine and bladder UPEC titers, with minimal kidney burden 24 h after UTI. In C3H/HeOuJ mice, UPEC burden was comparable in vehicle‐ and 1 mg/kg dapagliflozin‐treated groups both 24 h and 7 days after UTI. However, C3H/HeOuJ mice receiving 10 mg/kg dapagliflozin had increased UPEC titers in the urine, bladder and kidneys at both endpoints. Kidney injury and fibrosis markers, as well as kidney function, were similar in vehicle and dapagliflozin groups. In diabetic db/db mice receiving dapagliflozin, UPEC strain UTI89 titers were reduced 7 days after UTI compared to vehicle‐treated mice, but no difference in UPEC titers was observed when mice were infected with UPEC strain CFT073. Kidney injury and fibrosis markers and kidney function remained similar across treatment groups. Conclusions: Dapagliflozin does not consistently influence UTI susceptibility and shows limited impact on kidney injury or fibrosis, suggesting SGLT2 inhibitors have minimal effects on UTI‐related kidney complications.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K01 DK128379)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK115737)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK128088)
This publication has 51 references indexed in Scilit:
- Precision management of acute kidney injury in the intensive care unit: current state of the artIntensive Care Medicine, 2023
- Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic reviewInternational Urology and Nephrology, 2022
- Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trialThe Lancet Diabetes & Endocrinology, 2021
- Androgen exposure potentiates formation of intratubular communities and renal abscesses by Escherichia coliKidney International, 2018
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic reviewDiabetes Research and Clinical Practice, 2018
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trialsActa Diabetologica, 2018
- Diabetes mellitus and infection: an evaluation of hospital utilization and management costs in the United StatesJournal of Diabetes and its Complications, 2015
- Ribonuclease 7 is a potent antimicrobial peptide within the human urinary tractKidney International, 2011
- Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatmentInternational Journal of Antimicrobial Agents, 2008
- Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitusInternational Journal of Antimicrobial Agents, 2003